Covid-19 roundup: Fred Hutch cuts down fur­ther on lab work, Roche joins Re­gen­eron and Sanofi in IL-6 tri­als, Chi­na or­ders a vac­cine ef­fort

We’re now more than three-and a-half months in­to the out­break. That win­dow means we may soon get a glimpse of what works against Covid-19, but in the US the im­pact on all oth­er re­search may be just be­gin­ning.

→ When Seat­tle emerged as the first ma­jor metro area hit se­vere­ly by the coro­n­avirus, The Fred Hutchin­son Can­cer Re­search Cen­ter was one of the first ma­jor sci­en­tif­ic in­sti­tu­tions to send non-es­sen­tial per­son­nel home. Now they’re tak­ing fur­ther steps. While em­pha­siz­ing that they are not clos­ing, the cen­ter asked labs at its main Seat­tle cam­pus to lim­it their on-site per­son­nel to an “ab­solute min­i­mum” by yes­ter­day and trans­fer “al­most all” on-site work to re­mote work as ear­ly as Mon­day. They said it would like­ly last through April 24, if not longer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.